Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats

European Journal of Pharmacology

Volumn 466, Issue 1-2, 2003, Pages 99-111

  Löscher, Wolfgang ^a   Potschka, Heidrun ^a   Wlaź, Piotr ^a,b   Danysz, Wojciech ^c   Parsons, Christopher G ^c  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Antiepileptic drug; Epilepsy; Kindling; Nicotine induced; Nicotinic receptor; NMDA receptor; Seizure

Indexed keywords

1 AMINO 1,3 DIMETHYLCYCLOHEXANE; 1 AMINO 1,3,3 TRIMETHYLCYCLOHEXANE; AMANTADINE; ANTICONVULSIVE AGENT; DIZOCILPINE; MECAMYLAMINE; MEMANTINE; METHYLLYCACONITINE; MRZ 2 621; MRZ 2 625; MRZ 2 642; MRZ 2 705; N (1,3,3,5,5 PENTAMETHYLCYCLOHEXYL)PYRROLIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N,N DIMETHYL 1 AMINO 1,3,3,5,5 PENTAMETHYLCYCLOHEXANE; NERAMEXANE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; BRAIN CELL; CHOLINERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ELECTRIC SHOCK; EMBRYO; FEMALE; HIPPOCAMPUS; KINDLING; MOUSE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; RECEPTOR BLOCKING; SEIZURE;

EID: 0242500799     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01542-5     Document Type: Article

References (48)

1. Adamec R.E. Does kindling model anything clinically relevant? Biol. Psychiatry. 27:1990;249-279.
2. Albuquerque E.X., Pereira E.F.R., Castro N.G., Alkondon M., Reinhardt S., Schroder H., Maelicke A. Nicotinic receptors function in the mammalian central nervous system. Ann. N. Y. Acad. Sci. 757:1995;48-72.
3. Amador M., Dani J.A. MK-801 inhibition of nicotinic acetylcholine receptor channels. Synapse. 7:1991;207-215.
4. Berkovic S.F., Scheffer I.E. Genetics of the epilepsies. Epilepsia. 42(Suppl. 5):2001;16.
5. Bertrand D. Neuronal nicotinic acetylcholine receptors: their properties and alterations in autosomal dominant nocturnal frontal lobe epilepsy. Rev. Neurol. (Paris). 155:1999;457-462.
6. Bertrand D., Picard F., le Hellard S., Weiland S., Favre I., Phillips H., Bertrand S., Berkovic S.F., Malafosse A., Mulley J. How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia. 43(Suppl. 5):2002;112-122.
7. Bianchi C., Beani L. Acetylcholine. Frey H.-H., Janz D. Antiepileptic Drugs. 1998;139-151 Springer, Berlin.
8. Briggs C.A., McKenna D.G. Effect of MK-801 at the human α7 nicotinic acetylcholine receptor. Neuropharmacology. 35:1996;407-414.
9. Broide R.S., Salas R., Ji D., Paylor R., Patrick J.W., Dani J.A., De Biasi M. Increased sensitivity to nicotine-induced seizures in mice expressing the L250T α7 nicotinic acetylcholine receptor mutation. Mol. Pharmacol. 61:2002;695-705.
10. Buisson B., Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53:1998;555-563.
11. Burchfiel J.L., Duchowny M.S., Duffy F.H. Neuronal supersensitivity to acetylcholine induced by kindling in the rat hippocampus. Science. 204:1979;1096-1098.
12. Cain D.P. Excitatory neurotransmitters in kindling: excitatory amino acid, cholinergic, and opiate mechanisms. Neurosci. Biobehav. Rev. 13:1989;269-276.
13. Caulfield M.P., Higgins G.A. Mediation of nicotine-induced convulsions by central nicotinic receptors of the 'C6' type. Neuropharmacology. 22:1983;347-351.
14. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 280:1997;346-356.
15. Court J.A., Martin-Ruiz C., Graham A., Perry E. Nicotinic receptors in human brain: topography and pathology. J. Chem. Neuroanat. 20:2000;281-298.
16. Damaj M.I., Glassco W., Dukat M., Martin B.R. Pharmacological characterization of nicotine-induced seizures in mice. J. Pharmacol. Exp. Ther. 291:1999;1284-1291.
17. Dani J.A. Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry. 49:2001;166-174.
18. Dixit K.S., Dhasmana K.M., Saxena R.C., Kohli R.P. Antagonism of intracerebrally induced nicotinic convulsions in mice: a method for measuring the central antinicotinic activity of CNS acting agents. Psychopharmacologia. 19:1971;67-72.
19. Franceschini D., Paylor R., Broide R., Salas R., Bassetto L., Gotti C., De Biasi M. Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res. Mol. Brain Res. 98:2002;29-40.
20. Gil Z., Sack R.A., Kedmi M., Harmelin A., Orr-Urtreger A. Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor. NeuroReport. 13:2002;191-196.
21. Jarrot B. Epileptogenesis: biochemical aspects. Eadie M.J., Vajda F.J.E. Antiepileptic Drugs. Pharmacology and Therapeutics. 1999;87-121 Springer, Berlin.
22. Jirgensons A., Kauss V., Kalvinsh I., Gold M.R., Danysz W., Parsons C.G., Quack G. Synthesis and structure-affinity relationships of 1,3,5-alkylsubstituted cyclohexylamines binding at NMDA receptor PCP site. Eur. J. Med. Chem. 35:2000;555-565.
23. Jones S., Sudweeks S., Yakel J.L. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. 22:1999;555-561.
24. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
25. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol. 54:1998;721-741.
26. Löscher W. Animal models of epilepsy and epileptic seizures. Eadie M.J., Vajda F. Antiepileptic Drugs. Handbook of Experimental Pharmacology. 1999;19-62 Springer, Berlin.
27. Löscher W., Rogawski M.A. Epilepsy. Lodge D., Danysz W., Parsons C.G. Ionotropic Glutamate Receptors as Therapeutic Target. 2002;91-132 Graham Publ. Johnson City, TN.
28. Meldrum B.S. Identification and preclinical testing of novel antiepileptic compounds. Epilepsia. 38:1997;S7-S15.
29. Meyerhoff J.L., Bates V.E. Combined treatment with muscarinic and nicotinic cholinergic antagonists slows development of kindled seizures. Brain Res. 339:1985;386-389.
30. Moulard B., Picard F., le Hellard S., Agulhon C., Weiland S., Favre I., Bertrand S., Malafosse A., Bertrand D. Ion channel variation causes epilepsies. Brain Res. Brain Res. Rev. 36:2001;275-284.
31. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11:1998;523-569.
32. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology. 38:1999;85-108.
33. Parsons C.G., Danysz W., Quack G. Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists-in vitro characterisation. Amino Acids. 19:2000;157-166.
34. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. 1998;Academic Press, Sydney.
35. Peterson S.L., Albertson T.E. Neurotransmitter and neuromodulator function in the kindled seizure and state. Progr. Neurobiol. 19:1982;237-270.
36. Racine R.J. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr. Clin. Neurophys. 32:1972;281-294.
37. Rao T.S., Correa L.D., Lloyd G.K. Effects of lobeline and dimethylphenylpiperazinium iodide (DMPP) on N-methyl-D-aspartate (NMDA)-evoked acetylcholine release in vitro: evidence for a lack of involvement of classical neuronal nicotinic acetylcholine receptors. Neuropharmacology. 36:1997;39-50.
38. 3H]MK801 binding to the N-methyl-D-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites. J. Pharmacol. Exp. Ther. 247:1988;1025-1031.
39. Rundfeldt C., Hönack D., Löscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology. 29:1990;845-851.
40. Sato M., Racine R.J., McIntyre D.C. Kindling: basic mechanisms and clinical validity. Electroencephalogr. Clin. Neurophysiol. 76:1990;459-472.
41. Steinlein O. New functions for nicotinic acetylcholine receptors? Behav. Brain Res. 95:1998;31-35.
42. Stitzel J.A., Blanchette J.M., Collins A.C. Sensitivity to the seizure-inducing effects of nicotine is associated with strain-specific variants of the alpha 5 and alpha 7 nicotinic receptor subunit genes. J. Pharmacol. Exp. Ther. 284:1998;1104-1111.
43. Stitzel J.A., Jimenez M., Marks M.J., Tritto T., Collins A.C. Potential role of the alpha4 and alpha6 nicotinic receptor subunits in regulating nicotine-induced seizures. J. Pharmacol. Exp. Ther. 293:2000;67-74.
44. Stumpf C., Gogolak G. Actions of nicotine in the limbic system. Ann. N. Y. Acad. Sci. 142:1967;143.
45. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman Gilman A. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. 1996;177-198 McGraw-Hill, New York.
46. Turski L., Ikonomidou C., Turski W.A., Bortolotto Z.A., Cavalheiro E.A. Review: cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: a novel model of intractable epilepsy. Synapse. 3:1989;154-171.
47. Wahnschaffe U., Löscher W. Lack of changes in seizure susceptibility during the estrous cycle in kindled rats. Epilepsy Res. 13:1992;199-204.
48. Ward J.M., Cockcroft V.B., Lunt G.G., Smillie F.S., Wonnacott S. Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites. FEBS Lett. 270:1990;45-48.